



Universiteit
Leiden
The Netherlands

Smoking and the course of anxiety and depression

Jamal, M.

Citation

Jamal, M. (2014, May 22). *Smoking and the course of anxiety and depression*. Retrieved from <https://hdl.handle.net/1887/25815>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/25815>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/25815> holds various files of this Leiden University dissertation.

Author: Jamal, Mumtaz

Title: Smoking and the course of anxiety and depression

Issue Date: 2014-05-22

CHAPTER 4

Effect of Variation in BDNF Val⁶⁶Met Polymorphism, Smoking, and Nicotine Dependence on Symptom Severity of Depressive and Anxiety Disorders

Mumtaz Jamal

Willem Van der Does

Brenda W. J. H. Penninx

Submitted for publication

Abstract

Background. Smoking, especially nicotine dependence is associated with more severe symptoms of depression and anxiety disorders. However, the mechanisms underlying this association are unclear. We investigated the effect of BDNF Val⁶⁶Met polymorphism on the severity of depressive and anxiety symptoms in never-smokers, former smokers, and current smokers with and without nicotine dependence.

Methods. Participants from the Netherlands Study of Depression and Anxiety (NESDA) with a current diagnosis of depression and/or an anxiety disorder and with available BDNF Val⁶⁶Met polymorphism data were included (N=1,271). Dependent variables were severity of symptoms and independent variables were smoking status and BDNF genotype. Age, sex, education, recent negative life events, alcohol use, body mass index, and physical activity were treated as covariates.

Results. In Val⁶⁶Val carriers, nicotine-dependent smokers had more severe symptoms of depression and anxiety than non-dependent smokers, former smokers and never-smokers, whereas the latter three groups did not differ on severity of symptoms. In Met⁶⁶ carriers, there were no differences among the four smoking groups on severity of depression and anxiety. Nicotine dependence was the strongest predictor of severity of symptoms only in Val⁶⁶Val carriers.

Conclusions. In patients with an affective disorder, the relationship between nicotine dependence and symptom severity may be moderated by the BDNF Val⁶⁶Met polymorphism. These results may suggest that inherent genetic differences may be crucial for the worse behavioral outcome of nicotine, and that Val⁶⁶Val carriers may benefit most in mental health from smoking cessation.

Introduction

Epidemiological and clinical research has provided substantial evidence of an association of smoking with depression and anxiety disorders¹⁻⁵. Nicotine-dependent smokers have relatively high rates and more severe symptoms of depression and/ or anxiety as compared to non-dependent smokers, former- and never-smokers⁶⁻¹³. Twin studies have indicated that the association between smoking / nicotine dependence and depression/ anxiety can be explained by genetic¹⁴⁻¹⁸, and / or environmental factors^{14, 18-20}. However, the biological mechanisms underlying this association are not yet clear.

Brain-derived neurotrophic factor, (BDNF), an important regulatory protein and densely-expressed neurotrophin in the central and the peripheral nervous system, is a member of the nerve growth factor family^{21, 22}. It supports the survival, differentiation, and maintenance of neurons in the nervous system²³. It also regulates neurotransmitter systems dopamine²⁴ and serotonin²⁵ and is involved in neuroplasticity mechanisms such as long-term potentiation that underlies learning and memory²⁶⁻²⁸. The BDNF protein is encoded by the *BDNF* gene which, in humans, is located on chromosome 11²⁹. The single nucleotide polymorphism (SNP) rs6265 in BDNF gene results in an amino acid Valine-to-Methionine substitution at codon 66 (Val⁶⁶Met)³⁰.

The Val⁶⁶Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene may be a plausible candidate gene polymorphism underlying smoking-depression/ anxiety association. An association of this polymorphism has been found with affective disorders, and to some extent, also with smoking and other addictive behaviors. For example, previous research points to the involvement of variation in BDNF Val⁶⁶Met polymorphism in the pathophysiology of depression and anxiety disorders. Studies using magnetic resonance imaging found that Met⁶⁶ allele carriers with depression had smaller hippocampal volumes than Val⁶⁶Val carriers³¹. Smaller hippocampal volume is also a general characteristic of major depression³². A meta-analysis showed that the polymorphism was associated with major depressive disorder (MDD) only in

men, and that the MDD cases more often carried the Met⁶⁶ allele and were often in the homozygous Met⁶⁶Met genotype group³³. However, findings from two cohorts and a meta-analysis indicated that Val⁶⁶Met polymorphism is unlikely to play a role in the genetic susceptibility to depression in a large sample³⁴. One possible reason of this lack of association might be the non-clinical nature of the sample and self-report assessment of depression³⁴. Few studies investigated the relationship of combination of gene markers including BDNF Val⁶⁶Met polymorphism with depression. Though single-loci analyses did not show evidence of a significant positive association of the polymorphism with major depression, haplotype analysis of the combination of markers including BDNF rs6265³⁵⁻³⁷ produced significant associations with major depression. A recent mega-analysis of genome-wide association studies, however, failed to reveal an important role of this and other polymorphisms in major depression³⁸.

No association of BDNF Val⁶⁶Met polymorphism has been found with anxiety disorders including generalized anxiety disorder³⁹, panic disorder⁴⁰⁻⁴² and post-traumatic stress disorder⁴³ except in one community sample of children and adolescents⁴⁴.

Few studies examined the relevance of this polymorphism with addictive behaviors. For example, heroin-dependent Met⁶⁶ carriers were more often involved in drug-seeking behaviors and more cigarette use than Val⁶⁶Val homozygotes⁴⁵. In another study it was found that Met⁶⁶ carriers drank more alcohol per week, were more anxious to tolerate pressure and stress, and showed higher anticipatory cortisol response to stress than Val⁶⁶Val carriers⁴⁶. A recent study found that variation in BDNF Val⁶⁶Met polymorphism might be involved in smoking in schizophrenic patients⁴⁷. In a healthy adult German sample (N = 320), the frequency of the Met⁶⁶ allele of BDNF gene was higher in current and former smokers than in never-smokers⁴⁸. However, another study failed to replicate these findings⁴⁹. In a recent study with healthy Chinese male population (322 smokers, 306 non-smokers), age at the onset of smoking was associated with BDNF Val⁶⁶Met polymorphism such that smokers with the Met⁶⁶ allele initiated smoking significantly earlier than the Val⁶⁶Val

homozygous group⁵⁰. Thus, Met⁶⁶ variant of the BDNF gene seems to be involved in addictive behaviors.

In summary, although several studies supported the association of BDNF Val⁶⁶Met polymorphism with clinical major depressive disorder, a large mega-analysis failed to identify a role of this polymorphism in depression. There is also some evidence of an association of the Met⁶⁶ allele with smoking, although the number of studies and the sample sizes are limited. Smoking does appear to affect symptom severity in depression and anxiety disorders. It has been argued that psychiatric disorders may only be understood if both genetic and environmental factors are taken into account in the statistical models³⁸, and that, in order to elucidate the underlying molecular mechanisms that may explain the association between phenotypes, gene-by-environment interaction studies may be more useful⁵¹.

In the present study, we investigated the interaction between the BDNF gene Val⁶⁶Met polymorphism and smoking status on depressive and anxiety symptoms in a clinical sample. In a previous report, we found that nicotine-dependent smokers had more severe symptoms of depression and anxiety disorders than non-dependent smokers, former smokers, and never-smokers⁵². The current study investigated a possible involvement of the BDNF gene Val⁶⁶Met polymorphism in this association.

Methods

Participants and Data

Participants were selected from the Netherlands Study of Depression and Anxiety (NESDA), an on-going naturalistic prospective cohort study. NESDA started in September 2004 and investigates the long-term course and consequences of depression and anxiety disorders by examining clinical, psychosocial, biological and genetic determinants. At baseline, NESDA consisted of 2,981 participants (66.4 % females) between 18 to 65 years of age. Participants were recruited from mental health care, primary care, and the general population in order to represent the entire range of psychopathology. The sample consisted of persons with a current diagnosis of anxiety and/or depression (57 %), persons with a remitted history of the disorders (21 %) and healthy controls (22 %). The two exclusion criteria were (i) a primary diagnosis of a psychotic disorder, addiction disorder, obsessive-compulsive disorder, or bipolar disorder and (ii) not being fluent in Dutch. Data were collected on demographic, clinical, psychosocial, psychological, and physiological variables, and health behaviors including alcohol intake, smoking, drug use, and physical activity. For data collection, self-report questionnaires, interviews, a medical examination, a cognitive computer task, and blood and saliva samples were gathered. NESDA protocol was approved by the Ethical Review Board of the VU University Medical Center and the local review boards of participating centers. All participants provided written informed consent. Further details on the rationale, objectives, design and sample of NESDA were published elsewhere⁵³.

In the present study, we selected participants who had a current (past 6 months) diagnosis of depression and/or an anxiety disorder at the baseline assessment and for whom information on BDNF genotype was available (N= 1,271).

Measures

Smoking

Smoking behavior was measured by a questionnaire that covered past and current smoking behavior. Participants were classified into four groups based on their smoking status: never-smokers, former smokers, non-dependent smokers and nicotine-dependent smokers. Former smokers were those who stopped smoking definitively, and never-smokers were those who had no lifetime history of smoking. Nicotine dependence was assessed with the Fagerstrom Test for Nicotine Dependence (FTND)⁵⁴. The reliability and internal consistency of FTND have been shown in previous research⁵⁵. The FTND (score range: 0-10) assesses daily smoking rate, the interval between waking up and smoking the first cigarette, frequency of smoking after waking up, difficulty refraining from smoking in places where it is forbidden, and despite medical illness, and difficulty giving up the first cigarette in the morning. Current smokers with a score of 4 or higher on the FTND in the present study were defined as nicotine-dependent smokers^{12, 56}.

Psychopathology

The Composite International Diagnostic Interview (CIDI version 2.1)⁵⁷ was used to assess the DSM-IV criteria for anxiety and depressive disorders. The CIDI has high inter-rater reliability, high test-retest reliability and high validity for depressive and anxiety disorders⁵⁷.

Severity of depressive symptoms was assessed by the Inventory of Depressive Symptomatology (IDS). The IDS (score range: 0–84) is a 30-item self-report inventory which has shown high correlations with observer rated scales⁵⁸. The 21-item Beck Anxiety Inventory (BAI; score range: 0-62) was used to assess severity of anxiety symptoms⁵⁹. The symptoms of fear were measured with the 15-item Fear Questionnaire⁶⁰. We used two sub-scales of the Fear Questionnaire: (i) FQ items for social fear symptoms, and (ii) FQ items for agoraphobia symptoms⁶⁰. The sum score of both sub-scales ranges from 0 to 40. BAI and both subscales of FQ have sufficient internal consistency^{59, 61}.

Covariates

The Alcohol Use Disorder Identification Test (AUDIT) was used to assess alcohol intake⁶². The International Physical Activity Questionnaire (IPAQ) was used to measure physical activity. IPAQ estimates weekly energy expenditure based on daily physical activities⁶³. Negative life events in the past year were assessed with the List of Threatening Events Questionnaire (LTE-Q)⁶⁴. These events reflect the occurrence of stressful events such as serious personal illness or injury, death or loss of a loved one, and financial problems in the past year. Body mass index (BMI) was calculated (kg/m^2). Other covariates under study were age, sex, and education. These covariates were chosen because of their association with severity of affective symptoms⁶⁵⁻⁷⁰.

Genotyping

Venous blood samples were collected at baseline (between 0830 and 0930 hours) after overnight fasting and DNA was isolated using the FlexiGene DNA AGF3000 kit (Qiagen, Valencia, CA, USA) on an AutoGenFlex 3000 workstation (Autogen, Holliston, MA, USA). DNA concentrations were determined using the PicoGreens dsDNA Quantitation kit from Molecular Probes. Genotyping of the participants was conducted by Perlegen Sciences (Mountain View, CA, USA) using four proprietary, high-density oligonucleotide arrays. Detailed description of how genotyping was performed has been published elsewhere⁷¹. To extract the Val⁶⁶Met polymorphism from the whole genome data, PLINK software version 1.07 (<http://pngu.mgh.harvard.edu/~purcell/plink/>) was used. The imputation accuracy of rs6265 (Val⁶⁶Met polymorphism) was 99.9 % ($r^2_{\text{hat}} = 0.999$).

The current sample consists of 65.8 % Val⁶⁶Val and 3.5 % Met⁶⁶Met homozygotes, whereas 30.7 % were Val⁶⁶Met heterozygotes. We combined the low-frequency Met⁶⁶Met with Val⁶⁶Met and referred to the group as Met⁶⁶carriers⁴⁶.

Statistical Analyses

Preliminary analyses were conducted to ensure no violation of the assumptions of univariate and multivariate analysis. Normality of distributions, linearity, and multicollinearity, heterogeneity of variance, outlying scores, and coding errors were checked. The Hardy-Weinberg equilibrium for the BDNF polymorphism was tested using a chi-square test for goodness of fit. Differences on demographic and clinical characteristics between the groups stratified according to their smoking status were determined with one-way between-groups ANOVA and chi-square test for independence. The association of BDNF Val⁶⁶Met polymorphism was examined, separately, with smoking status, nicotine dependence, and with the symptoms of depression and anxiety disorders, using chi-square test for independence, independent-samples t-test, and multivariate ANCOVA, respectively. Next, the estimates of the interaction effects of genotype and smoking status on the symptoms of depression and anxiety disorders were computed with multivariate ANCOVA while controlling for the covariates on which the groups differed significantly. In order to control for the potentially confounding influences of the covariates on the main and the interaction effects of the BDNF genotype and smoking status, we entered all the covariate x smoking status and the covariate x BDNF gene interaction terms in the same model that tests the BDNF gene x smoking status interaction term, along with the simple effects of the covariates^{72, 73}. Significant interaction effects were followed up by univariate ANCOVAs, run separately for Val⁶⁶Val and Met⁶⁶ carriers. Eta squared and partial eta squared were used as the measures of effect size, and alpha level of 0.05 was used. Finally, the predictors of symptom severity were examined separately for Val⁶⁶Val and Met⁶⁶ carriers using multiple linear regression analyses. Two models were fitted in each regression analysis. In the first model, we entered age, sex, education, past year negative life events, alcohol intake and body mass index, and in the second model we added nicotine dependence. Thus the estimates provided from the final model included all variables. Analyses were run in PASW (V. 19.0) for windows.

Results

Preliminary analyses did not indicate any serious violation of the assumptions of univariate and multivariate tests. The genotype distributions in the four smoking groups did not deviate significantly from the Hardy-Weinberg Equilibrium (never-smokers: $p = 0.5$; former smokers: $p = 0.6$; non-dependent smokers: $p = 0.3$; nicotine-dependent smokers: $p = 0.7$).

Sample Characteristics

Of the 1,271 participants, 24.6 % were never-smokers, 31.0 % were former smokers, and 44.4 % were current smokers. Of the current smokers, 46.5 % were nicotine-dependent. The smoking groups differed significantly with respect to age ($F_{(3, 1267)} = 26.1$; $p < 0.001$), education ($F_{(3, 1267)} = 12.1$; $p < 0.001$), past year negative life events ($F_{(3, 1267)} = 6.6$; $p < 0.001$), alcohol intake ($F_{(3, 1252)} = 33.8$; $p < 0.001$), and body mass index ($F_{(3, 1266)} = 5.0$; $p < 0.01$). No group differences were found in physical activity, sex distribution, and BDNF genotype ($ps > 0.05$). Post-hoc comparisons between the smoking groups for significant association of continuous variables are presented in table 1.

Association of BDNF Genotype with Smoking, and with Symptom Severity

No association of smoking status with BDNF genotype was found. The four smoking groups did not differ significantly in allele distribution ($p > 0.05$). We also examined allele distribution by collapsing the four smoking groups into two groups of current smokers (non-dependent and dependent) and non-smokers (former and never-smokers), however, the difference did not reach significance ($p > 0.05$).

Multivariate ANCOVA revealed that the main effect of BDNF Val⁶⁶Met polymorphism on the severity of symptoms of depression, general anxiety, social anxiety and agoraphobia was non-significant ($ps > 0.05$).

Table 1. Participants' characteristics stratified according to their smoking status

Sociodemographic variables and health behaviors	Never- smokers N = 313		Former smokers N = 394		Current smokers				Effect size ²	Tukey ³
					Non- dependent N = 302		Nicotine- dependent N = 262			
Age (Mean, SD)	38.7	12.8	45.3	11.8	38.4	11.9	41.7	10.7	0.06***	FS>D>FS,NS
Sex, F (N, %)	220	70.3	262	66.5	208	68.9	164	62.6	ns	
Education, in years (Mean, SD)	12.2	3.2	12.1	3.3	11.8	3.1	10.7	3.1	0.03***	D<nD,FS,NS
Past year negative life events (Mean, SD)	0.9	1.1	0.9	1.0	1.0	1.2	1.3	1.4	0.02***	D>nD,FS,NS
Alcohol use (Mean, SD)	2.9	3.4	4.8	4.6	6.5	5.5	6.5	6.7	0.07***	nD,D>FS>NS
Physical activity (Mean, SD) ¹	3.4	2.9	3.6	3.0	3.9	3.5	3.6	3.6	ns	
Body mass index (Mean, SD)	25.6	5.2	26.4	5.1	24.8	4.8	25.5	5.6	0.01**	nD<FS
BDNF genotype (N, %)									ns	
Val ⁶⁶ Val carriers	211	67.4	268	68.0	183	60.6	174	66.4		
Met ⁶⁶ carriers	102	32.6	126	32.0	119	39.4	88	33.6		

*** $p < 0.001$, ** $p < 0.01$, * $p < 0.05$ ¹Mean met-minutes (ratio of energy expenditure during activity to energy expenditure at rest) divided by 1000²ns: non-significant³Only significant results are shown; NS: never-smokers, FS: former smokers, nD: non-dependent, D: nicotine-dependent

Interaction Effect of BDNF Genotype and Smoking Status on Symptom Severity

A multivariate ANCOVA showed that the BDNF genotype and smoking status interaction effect was significant for symptoms of depression ($F_{(3, 1230)} = 3.1$; $p < 0.05$; partial $\eta^2 = 0.01$) and anxiety ($F_{(3, 1230)} = 2.8$; $p < 0.05$; partial $\eta^2 = 0.01$), while non-significant for symptoms of social anxiety and agoraphobia ($ps > 0.05$).

The subsequent univariate ANCOVAs revealed that in Val⁶⁶Val carriers, the main effect of smoking status on symptoms of depression ($F_{(3, 812)} = 8.7$; $p < 0.001$; partial $\eta^2 = 0.03$) and general anxiety ($F_{(3, 813)} = 5.6$; $p = 0.001$; partial $\eta^2 = 0.02$) was significant. Pairwise comparisons showed that nicotine-dependent smokers had significantly more severe symptoms of depression and general anxiety than non-dependent smokers, former smokers, and never-smokers ($ps < 0.05$). Never-smokers, former smokers, and non-dependent current smokers did not differ significantly from each other ($ps > 0.05$) on severity of depressive and anxiety symptoms (table 2).

In Met⁶⁶ carriers, the main effect of smoking status on severity of symptoms of depression and general anxiety was non-significant in the univariate ANCOVA ($ps > 0.1$), suggesting that smoking groups carrying Met⁶⁶ allele did not differ significantly from each other on severity of symptoms of depression and general anxiety (table 2).

Table 2. Estimates of the severity of symptoms of depression and anxiety disorder in different smoking groups stratified according to their BDNF genotype^a

Severity of symptoms	Never-smokers			Former smokers			Current smokers (nD) ^b			Current smokers (D) ^b			Partial η^2
	Mean	SE	95% CI	Mean	SE	95% CI	Mean	SE	95% CI	Mean	SE	95% CI	
	BDNF Val ⁶⁶ Val carriers												
Symptoms of depression	23.1	4.2	14.9, 31.3	26.0	1.3	23.4, 28.7	33.1	2.1	29.0, 37.2	43.8	4.9	34.2, 53.4	.03***
Symptoms of anxiety	11.3	3.6	4.2, 18.3	14.2	1.1	11.9, 16.4	18.9	1.8	15.4, 22.4	27.1	4.2	18.8, 35.3	.02***
	BDNF Met ⁶⁶ carriers												
Symptoms of depression	25.7	5.4	15.0, 36.3	28.1	2.0	24.1, 32.0	30.2	2.4	25.5, 34.9	32.9	6.1	21.0, 44.9	ns
Symptoms of anxiety	13.3	4.6	4.3, 22.4	15.4	1.7	12.0, 18.7	17.5	2.0	13.6, 21.5	18.1	5.1	8.0, 28.3	ns

*** $p \leq 0.001$ ^aAdjusted for covariates and their interactions with smoking and genotype.^bnD: non-dependent; D: nicotine-dependent.

ns: non-significant.

Predictors of Symptom Severity

Regression analyses indicated that in the Val⁶⁶Val group, the first model with age, sex, education, negative life events, alcohol intake, and body mass index explained 7.6 % of the variance in severity of depression ($p < 0.001$). The second model that added nicotine dependence accounted for an additional 5 % of the significant variance ($R^2 = 0.125$; $p < 0.001$). In Met⁶⁶ carriers, only the first model with age, sex, education, negative life events, alcohol intake, and body mass index explained significant variance ($R^2 = 0.07$, $p < 0.05$).

The same pattern emerged with anxiety severity as the dependent measure. In the Val⁶⁶Val group, the first model explained 6.4 % variance in severity of anxiety ($p = 0.001$), and the second model with nicotine dependence accounted for an additional 5 % of the significant variance ($R^2 = 0.12$; $p < 0.001$). In Met⁶⁶ carriers, only the first model explained significant variance ($R^2 = 0.10$; $p < 0.01$).

Nicotine dependence was the strongest significant predictor of the symptoms of depression and anxiety only in Val⁶⁶Val carriers (table 3).

Table 3. Regression of nicotine dependence on the severity of symptoms stratified according to the BDNF genotype

	BDNF Val ⁶⁶ Val carriers				BDNF Met ⁶⁶ carriers*			
Predictors	B	SE	B	p	B	SE	β	p
Severity of depression								
Age	-0.07	0.06	-.07	ns	0.01	0.07	.01	ns
Sex	0.78	1.39	.03	ns	-0.03	1.82	.001	ns
Education	-0.49	0.21	-.13	*	-0.67	0.27	-.18	*
Negative life events	0.55	0.51	.06	ns	0.06	0.77	.01	ns
Alcohol intake	0.01	0.12	.004	ns	-0.04	0.17	-.02	ns
BMI	0.38	0.13	.16	**	0.31	0.17	0.13	ns
Nicotine dependence	1.11	0.26	.24	***	0.58	0.34	.12	ns
Severity of general anxiety								
Age	-0.05	0.05	-.05	ns	-0.01	0.06	-.01	ns
Sex	-0.10	1.18	-.004	ns	-1.40	1.56	-.06	ns
Education	-0.45	0.17	-.14	*	-0.90	0.23	-.27	***
Negative life events	0.53	0.44	.06	ns	-0.26	0.67	-.03	ns
Alcohol intake	0.07	0.10	.04	ns	0.05	0.14	.02	ns
BMI	0.20	0.11	.10	ns	0.21	0.14	.11	ns
Nicotine dependence	0.96	0.22	.24	***	0.41	0.29	.10	ns
*** $p < 0.001$; ** $p < 0.01$; * $p < 0.05$ ns: non-significant								

Discussion

We previously reported that nicotine-dependent smokers had more severe symptoms of depression and anxiety disorders than non-dependent smokers, former smokers, and never-smokers⁵². In the present study, we examined the role of the BDNF Val⁶⁶Met polymorphism in this association.

The BDNF polymorphism had no direct effect on smoking status and on the severity of affective symptoms in the present sample. However, we did observe an interaction of smoking status and BDNF polymorphism with the symptoms of depression and anxiety. In Val⁶⁶Val carriers, nicotine-dependent smokers had more severe symptoms of depression and anxiety disorder than non-dependent smokers, former smokers and never-smokers, whereas the latter three groups were comparable in symptom severity. In Met⁶⁶ carriers no differences among the four smoking groups were found in symptoms of depression and anxiety. We also found that after controlling for the potential confounding variables, nicotine dependence was the strongest predictor of the symptoms of depression and anxiety only in Val⁶⁶Val homozygotes. These findings suggest that genetic predisposition and nicotine dependence may act interdependently in the severity of symptoms of affective disorders.

These findings need to be replicated as there is no previous report on the interacting effects of BDNF gene and smoking status on depressive and anxiety symptoms. Most of the previous literature is based on association studies that look for a direct relationship of BDNF Val⁶⁶Met polymorphism with depression, or with smoking, and most of the studies examined genotype or allele frequencies. In order to elucidate the underlying molecular mechanisms through which variation in the BDNF gene may lead to severity of symptoms, gene-by-environment interaction studies may be more useful^{38, 51}.

The observed association might be interpreted in the context of previous MRI research which shows that Val⁶⁶Val genotype is associated with reduced hippocampal gray matter volumes in healthy Caucasian participants⁷⁴. Further, reduced hippocampal gray matter volume has also been associated with major depression³². Thus, nicotine-dependent smokers who carry Val⁶⁶Val variant of the BDNF gene may have reduced hippocampal gray matter volume and thus may experience more severe symptoms than Met⁶⁶ carriers whose brain morphology may not be depression-vulnerable. This speculation has been supported by animal research. In a recent animal model of depression, nicotine administration exacerbated depressive-like behavior in inbred Wistar-Kyoto (WKY) rats, which had reduced hippocampal volume but not in the control Wistar rats with comparatively large hippocampal volume⁷⁵. Research has also shown greater genotypic variability among WKY rats compared to other inbred strains^{76, 77}. It has been proposed that the differential responses of WKY and Wistar rats to nicotine may reflect genetic differences⁷⁵. Thus, the current findings suggest that genetic differences are important determinants to explain worse behavioral outcome of nicotine in some individuals but not in others. However, this theory needs to be confirmed in future MRI and genetic investigations.

This study has some limitations which should be taken into account. Firstly, we investigated only one polymorphism, therefore it is likely that other polymorphisms in the BDNF gene or other genes are involved. Secondly, the study is cross-sectional and causality cannot be inferred. Thirdly, our findings may not be generalizable to other ethnic groups or homogenous age groups.

A strength of our study is the relatively large sample size compared to prior research in this area. We investigated patients with a diagnosed psychiatric disorder, unlike most previous studies that used samples from general population. The depression and anxiety disorder diagnoses were made according to DSM-IV criteria, whereas most previous studies assessed symptoms using self-report measures. The study sample is ethnically homogenous and we were able to control for a large number of covariates.

Despite a well-established association between smoking and depression and anxiety disorders, the mechanisms underlying this association have rarely been investigated from a genetic perspective. Only few studies have investigated the interacting effects of genetic predisposition and depressive symptoms on smoking. The two short alleles of DRD4 gene are associated with self-medicating smoking practices in depressed individuals⁷⁸. Similarly, smokers with severe depressive symptoms were progressing to a higher level of smoking only if they had DRD2A1 allele⁷⁹. However, these studies support the notion of smoking as a self-medicating agent to alleviate depressive symptoms. The theory, that smoking is a vulnerability factor in depression and anxiety has recently been investigated using the rs1051730 SNP variant located in the nicotine acetylcholine receptor gene cluster on chromosome 15. Self-reported smoking was positively associated with the prevalence of both anxiety and depression, and the measured polymorphism was positively associated with smoking. However, no association of the polymorphism with either anxiety or depression was found among smokers suggesting that smoking is not a causal factor of anxiety and depression⁸⁰. Our results, however, are supportive of the ‘smoking as a vulnerability factor in depression/ anxiety’ theory. We found a genotype-dependent dose-response relationship between nicotine dependence and symptom severity. Though, this theory could not be elucidated in the current study because of its cross-sectional nature, it may provide a starting point for understanding the neurobiological links between smoking or nicotine dependence and affective disorders.

This study has clinical implications, for example, Val⁶⁶Val carriers may benefit most from smoking cessation or lowering amount of smoking. It could

still be that smoking in this group is a failed attempt at self-medication. Thus, future study could focus on immediate versus longer-term subjective effects of lighting a cigarette in this group. If it turns out that smoking reduces anxiety in the short-term, this group may particularly benefit from other interventions that reduce anxiety while they attempt to quit.

This study, also, has important implications for future molecular research on smoking-psychopathology association. Given the high prevalence of depression and anxiety in smokers, it is important to focus on investigating the genetic and biological influences to elucidate the mechanisms underlying the association between smoking and affective disorders. Similarly, ethnicity should be given consideration because of the ethnic differences in genotype and allele frequencies⁴². Moreover, DSM assessment for nicotine dependence may be more useful for identifying smokers vulnerable to depression and anxiety⁸¹. Understanding of genetic influences on smoking-psychopathology association may be significant for guiding smoking prevention and intervention programs in identifying smokers, particularly those with nicotine dependence who are vulnerable to adverse outcomes

References

1. Chaiton MO, Cohen JE, O'Loughlin J, Rehm J. (2009). A systematic review of longitudinal studies on the association between depression and smoking in adolescents. *BMC Public Health*, 9: 1-11.
2. Cosci F, Knuts IJE, Abrams K, Griez EJJ, Schruers KRJ. (2010). Cigarette smoking and panic: a critical review of the literature. *Journal of Clinical Psychiatry*, 71(5): 606-615.
3. Morrell HER, Cohen LM. (2006). Cigarette smoking, anxiety, and depression. *Journal of Psychopathology and Behavioral Assessment*, 28(4): 283-297.
4. Moylan S, Jacka FN, Pasco JA, Berk M. (2013). How cigarette smoking may increase the risk of anxiety symptoms and anxiety disorders? a critical review of biological pathways. *Brain and Behavior*, 3(3): 302-326.
5. Zvolensky MJ, Feldner MT, Leen-Feldner EW, McLeish AC. (2005). Smoking and panic attacks, panic disorder, and agoraphobia: a review of the empirical literature. *Clinical Psychology Review*, 25(6): 761-789.
6. Breslau N, Kilbey MM, Andreski P. (1991). Nicotine dependence, major depression and anxiety in young adults. *Archives of General Psychiatry*, 48(12): 1069-1074.
7. Breslau N, Kilbey MM, Andreski P. (1993). Nicotine dependence and major depression: new evidence from a prospective investigation. *Archives of General Psychiatry*, 50(1): 31-35.
8. Brown C, Madden PAF, Palenchar DR, Cooper-Patrick L. (2000). The association between depressive symptoms and cigarette smoking in an urban primary care sample. *International Journal of Psychiatry in Medicine*, 30(1): 15-26.
9. Fergusson DM, Lynskey MT, Horwood LJ. (1996). Comorbidity between depressive disorders and nicotine dependence in a cohort of 16-year-olds. *Archives of General Psychiatry*, 53(11): 1043-1047.
10. John U, Meyer C, Rumpf HJ, Hapke U. (2004a). Depressive disorders are related to nicotine dependence in the population but do not necessarily hamper smoking cessation. *Journal of Clinical Psychiatry*, 65(2): 169-176.
11. John U, Meyer C, Rumpf HJ, Hapke U. (2004b). Smoking, nicotine dependence and psychiatric comorbidity: a population-based study including smoking cessation after three years. *Drug and Alcohol Dependence*, 76(3): 287-295.
12. Pedersen W, von Soest T. (2009). Smoking, nicotine dependence and mental health among young adults: a 13-year population-based longitudinal study. *Addiction*, 104(1): 129-137.
13. Strong DR, Cameron A, Feuer S, Cohn A, Abrantes AM, Brown RA. (2010). Single versus recurrent depression history: differentiating risk factors among current US smokers. *Drug and Alcohol Dependence*, 109(1-3): 90-95.
14. Edwards AC, Maes HH, Pedersen NL, Kendler KS. (2011). A population-based twin study of the genetic and environmental relationship of major depression, regular tobacco use and nicotine dependence. *Psychological Medicine*, 41(2): 395-405.

15. Kendler KS, Neale MC, MacLean CJ, Heath AC, Eaves LJ, Kessler RC. (1993). Smoking and major depression: a causal analysis. *Archives of General Psychiatry*, 50(1): 36-43.
16. Korhonen T, Broms U, Varjonen J, Romanov K, Koskenvuo M, Kinnunen T, Kaprio J. (2007). Smoking behaviour as a predictor of depression among Finnish men and women: a prospective cohort study of adult twins. *Psychological Medicine*, 37(5): 705-715.
17. Lyons M, Hitsman B, Xian H, Panizzon MS, Jerskey BA, Santangelo S, . . . Tsuang MT. (2008). A twin study of smoking, nicotine dependence, and major depression in men. *Nicotine and Tobacco Research*, 10(1): 97-108.
18. McCaffery JM, Stanton C, Papandonatos GD, Lloyd-Richardson EE, Niaura R. (2008). Depressive symptoms and cigarette smoking in twins from the National Longitudinal Study of Adolescent Health. *Health Psychology*, 27(3): S207-S215.
19. McCaffery JM, Niaura R, Swan GE, Carmelli D. (2003). A study of depressive symptoms and smoking behavior in adult male twins from the NHLBI twin study. *Nicotine and Tobacco Research*, 5(1): 77-83.
20. Reichborn-Kjennerud T, Roysamb E, Tambs K, Torgersen S, Kringlen E, Magnus P, Harris JR. (2004). Genetic and environmental influences on the association between smoking and panic attacks in females: a population-based twin study. *Psychological Medicine*, 34(7): 1271-1277.
21. Conner JM, Lauterborn JC, Yan Q, Gall CM, Varon S. (1997). Distribution of brain-derived neurotrophic factor (BDNF) protein and mRNA in the normal adult rat CNS: evidence for anterograde axonal transport. *Journal of Neuroscience*, 17(7): 2295-2313.
22. Leibrock J, Lottspeich F, Hohn A, Hofer M, Hengeler B, Masiakowski P, . . . Barde YA. (1989). Molecular cloning and expression of brain-derived neurotrophic factor. *Nature*, 341(6238): 149-152.
23. Huang EJ, Reichardt LF. (2001). Neurotrophins: roles in neuronal development and function. *Annual Review of Neuroscience*, 24: 677-736.
24. Hyman C, Hofer M, Barde YA, Juhasz M, Yancopoulos GD, Squinto SP, Lindsay RM. (1991). BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. *Nature*, 350(6315): 230-232.
25. Mossner R, Daniel S, Albert D, Heils A, Okladnova O, Schmitt A, Lesch KP. (2000). Serotonin transporter function is modulated by brain-derived neurotrophic factor (BDNF) but not nerve growth factor (NGF). *Neurochemistry International*, 36(3): 197-202.
26. Korte M, Carroll P, Wolf E, Brem G, Thoenen H, Bonhoeffer T. (1995). Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor. *Proceedings of the National Academy of Sciences of the United States of America*, 92(19): 8856-8860.
27. Mizuno M, Yamada K, Olariu A, Nawa H, Nabeshima T. (2000). Involvement of brain-derived neurotrophic factor in spatial memory formation and maintenance in a radial arm maze test in rats. *Journal of Neuroscience*, 20(18): 7116-7121.

28. Thoenen H. (1995). Neurotrophins and neuronal plasticity. *Science*, 270(5236): 593-598.
29. Maisonpierre PC, Lebeau MM, Espinosa R, Ip NY, Belluscio L, Delamonte SM, . . . Yancopoulos GD. (1991). Human and rat brain-derived neurotrophic factor and neurotrophin-3: gene structures, distributions, and chromosomal localizations. *Genomics*, 10(3): 558-568.
30. Bath KG, Lee FS. (2006). Variant BDNF (Val⁶⁶Met) impact on brain structure and function. *Cognitive Affective and Behavioral Neuroscience*, 6(1): 79-85.
31. Frodl T, Schuele C, Schmitt G, Born C, Baghai T, Zill P, . . . Meisenzahl EM. (2007). Association of the brain-derived neurotrophic factor Val⁶⁶Met polymorphism with reduced hippocampal volumes in major depression. *Archives of General Psychiatry*, 64(4): 410-416.
32. Videbech P, Ravnkilde B. (2004). Hippocampal volume and depression: a meta-analysis of MRI studies. *American Journal of Psychiatry*, 161(11): 1957-1966.
33. Verhagen M, Van der Meij A, Van Deurzen PAM, Janzing JGE, Arias-Vasquez A, Buitelaar JK, Franke B. (2010). Meta-analysis of the BDNF Val⁶⁶Met polymorphism in major depressive disorder: effects of gender and ethnicity. *Molecular Psychiatry*, 15(3): 260-271.
34. Chen L, Lawlor DA, Lewis SJ, Yuan W, Abdollahi MR, Timpson NJ, . . . Shugart YY. (2008). Genetic association study of BDNF in depression: finding from two cohort studies and a meta-analysis. *American Journal of Medical Genetics Part B-Neuropsychiatric Genetics*, 147B(6): 814-821.
35. Anttila S, Huuhka K, Huuhka M, Rontu R, Hurme M, Leinonen E, Lehtima T. (2007). Interaction between 5-HT1A and BDNF genotypes increases the risk of treatment-resistant depression. *Journal of Neural Transmission*, 114(8): 1065-1068.
36. Schumacher J, Abou Jamra R, Becker T, Ohlraun S, Klopp N, Binder EB, . . . Cichon S. (2005). Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. *Biological Psychiatry*, 58(4): 307-314.
37. Zhang K, Yang C, Xu Y, Sun N, Yang H, Liu J, . . . Shen Y. (2010). Genetic association of the interaction between the BDNF and GSK3B genes and major depressive disorder in a Chinese population. *Journal of Neural Transmission*, 117(3): 393-401.
38. Sullivan PF, Daly MJ, Ripke S, Lewis CM, Lin D-Y, Wray NR, . . . Viktorin A. (2013). A mega-analysis of genome-wide association studies for major depressive disorder. *Molecular Psychiatry*, 18(4): 497-511.
39. Surtees PG, Wainwright NWJ, Willis-Owen SAG, Sandhu MS, Luben R, Day NE, Flint J. (2007). No association between the BDNF Val⁶⁶Met polymorphism and mood status in a non-clinical community sample of 7389 older adults. *Journal of Psychiatric Research*, 41(5): 404-409.
40. Lam P, Cheng CY, Hong CJ, Tsai SJ. (2004). Association study of a brain-derived neurotrophic factor (Val⁶⁶Met) genetic polymorphism and panic disorder. *Neuropsychobiology*, 49(4): 178-181.

41. Otowa T, Shimada T, Kawamura Y, Liu X, Inoue K, Sugaya N, . . . Sasaki T. (2009). No association between the brain-derived neurotrophic factor gene and panic disorder in Japanese population. *Journal of Human Genetics*, 54(8): 437-439.
42. Shimizu E, Hashimoto K, Koizumi H, Kobayashi K, Itoh K, Mitsumori M, . . . Iyo M. (2005). No association of the brain-derived neurotrophic factor (BDNF) gene polymorphisms with panic disorder. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 29(5): 708-712.
43. Lee HJ, Kang RH, Lim SW, Paik JW, Choi MJ, Lee MS. (2006). No association between the brain-derived neurotrophic factor gene Val⁶⁶Met polymorphism and posttraumatic stress disorder. *Stress and Health*, 22(2): 115-119.
44. Tocchetto A, Salum GA, Blaya C, Teche S, Isolan L, Bortoluzzi A, . . . Manfro GG. (2011). Evidence of association between Val⁶⁶Met polymorphism at BDNF gene and anxiety disorders in a community sample of children and adolescents. *Neuroscience Letters*, 502(3): 197-200.
45. Greenwald MK, Steinmiller CL, Śliwerska E, Lundahl L, Burmeister M. (2013). BDNF Val⁶⁶Met genotype is associated with drug-seeking phenotypes in heroin-dependent individuals: a pilot study. *Addiction Biology*, 18(5): 836-845.
46. Colzato LS, Van der Does AJW, Kouwenhoven C, Elzinga BM, Hommel B. (2011). BDNF Val⁶⁶Met polymorphism is associated with higher anticipatory cortisol stress response, anxiety, and alcohol consumption in healthy adults. *Psychoneuroendocrinology*, 36(10): 1562-1569.
47. Wang ZR, Zhou DF, Cao LY, Tan YL, Zhang XY, Li J, . . . Kosten TR. (2007). Brain-derived neurotrophic factor polymorphisms and smoking in schizophrenia. *Schizophrenia Research*, 97(1-3): 299-301.
48. Lang UE, Sander T, Lohoff FW, Hellweg R, Bajbouj M, Winterer G, Gallinat J. (2007). Association of the Met⁶⁶ allele of brain-derived neurotrophic factor (BDNF) with smoking. *Psychopharmacology*, 190(4): 433-439.
49. Montag C, Basten U, Stelzel C, Fiebach CJ, Reuter M. (2008). The BDNF Val⁶⁶Met polymorphism and smoking. *Neuroscience Letters*, 442(1): 30-33.
50. Zhang XY, Chen DC, Xiu MH, Luo X, Zuo L, Haile CN, . . . Kosten TR. (2012). BDNF Val⁶⁶Met variant and smoking in a Chinese population. *Plos One*, 7(12): 1-5.
51. Duncan LE, Hutchison KE, Carey G, Craighead WE. (2009). Variation in brain-derived neurotrophic factor (BDNF) gene is associated with symptoms of depression. *Journal of Affective Disorders*, 115(1-2): 215-219.
52. Jamal M, Van der Does AJW, Cuijpers P, Penninx BWJH. (2012). Association of smoking and nicotine dependence with severity and course of symptoms in patients with depressive or anxiety disorder. *Drug and Alcohol Dependence*, 126(1-2): 138-146.
53. Penninx BWJH, Beekman ATF, Smit JH, Zitman FG, Nolen WA, Spinhoven P, . . . NESDA Research Consortium. (2008). The Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and methods. *International Journal of Methods in Psychiatric Research*, 17(3): 121-140.
54. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom K-O. (1991). The Fagerström test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. *British Journal of Addiction*, 86(9): 1119-1127.

55. Pomerleau CS, Carton SM, Lutzke ML, Flessland KA, Pomerleau OF. (1994). Reliability of the Fagerstrom tolerance questionnaire and the Fagerstrom test for nicotine dependence. *Addictive Behaviors*, 19(1): 33-39.
56. Burling AS, Burling TA. (2003). A comparison of self-report measures of nicotine dependence among male drug/alcohol-dependent cigarette smokers. *Nicotine and Tobacco Research*, 5(5): 625-633.
57. Wittchen H-U, Robins LN, Cottler LB, Sartorius N, Burke JD, Regier D. (1991). Cross-cultural feasibility, reliability, and sources of variance of the composite international diagnostic interview (CIDI): the multicentre WHO/ADAMHA field trials. *British Journal of Psychiatry*, 159: 645-653.
58. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. (1996). The inventory of depressive symptomatology (IDS): psychometric properties. *Psychological Medicine*, 26(3): 477-486.
59. Beck AT, Brown G, Epstein N, Steer RA. (1988). An inventory for measuring clinical anxiety: psychometric properties. *Journal of Consulting and Clinical Psychology*, 56(6): 893-897.
60. Marks IM, Mathews AM. (1979). Brief standard self-rating for phobic patients. *Behaviour Research and Therapy*, 17(3): 263-267.
61. Vanzuuren FJ. (1988). The fear questionnaire: some data on validity, reliability, and layout. *British Journal of Psychiatry*, 153: 659-662.
62. Babor TF, Kranzler HR, Lauerma RJ. (1989). Early detection of harmful alcohol consumption: comparison of clinical, laboratory, and self-report screening procedures. *Addictive Behaviors*, 14(2): 139-157.
63. Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, . . . Oja P. (2003). International physical activity questionnaire: 12-country reliability and validity. *Medicine and Science in Sports and Exercise*, 35(8): 1381-1395.
64. Brugha T, Bebbington P, Tennant C, Hurry J. (1985). The list of threatening experiences: a subset of 12 life event categories with considerable long-term contextual threat. *Psychological Medicine*, 15(1): 189-194.
65. Caldwell TM, Rodgers B, Jorm AF, Christensen H, Jacomb PA, Korten AE, Lynskey MT. (2002). Patterns of association between alcohol consumption and symptoms of depression and anxiety in young adults. *Addiction*, 97(5): 583-594.
66. Da Silva MA, Singh-Manoux A, Brunner EJ, Kaffashian S, Shipley MJ, Kivimaki M, Nabi H. (2012). Bidirectional association between physical activity and symptoms of anxiety and depression: the Whitehall II study. *European Journal of Epidemiology*, 27(7): 537-546.
67. Leach LS, Christensen H, Windsor TD, Butterworth P, Mackinnon AJ. (2008). Gender differences in depression and anxiety across the adult lifespan: the role of psychosocial mediators. *Social Psychiatry and Psychiatric Epidemiology*, 43(12): 983-998.

68. Pillay AL, Sargent CA. (1999). Relationship of age and education with anxiety, depression, and hopelessness in a South African community sample. *Perceptual and Motor Skills*, 89(3): 881-884.
69. Zhao G, Ford ES, Dhingra S, Li C, Strine TW, Mokdad AH. (2009). Depression and anxiety among US adults: associations with body mass index. *International Journal of Obesity*, 33(2): 257-266.
70. Spinhoven P, Elzinga BM, Hovens JGFM, Roelofs K, Van Oppen P, Zitman FG, Penninx BWJH. (2011). Positive and negative life events and personality traits in predicting course of depression and anxiety. *Acta Psychiatrica Scandinavica*, 124(6): 462-473.
71. Boomsma DI, Willemsen G, Sullivan PF, Heutink P, Meijer P, Sondervan D, . . . Penninx BWJH. (2008). Genome-wide association of major depression: description of samples for the GAIN major depressive disorder study: NTR and NESDA biobank projects. *European Journal of Human Genetics*, 16(3): 335-342.
72. Yzerbyt VY, Muller D, Judd CM. (2004). Adjusting researchers' approach to adjustment: on the use of covariates when testing interactions. *Journal of Experimental Social Psychology*, 40(3): 424-431.
73. Keller M. (2014). Gene x environment interaction studies have not properly controlled for potential confounders: the problem and the (simple) solution. *Biological Psychiatry*, 75: 18-24.
74. Pezawas L, Verchinski BA, Mattay VS, Callicott JH, Kolachana BS, Straub RE, . . . Weinberger DR. (2004). The brain-derived neurotrophic factor Val⁶⁶Met polymorphism and variation in human cortical morphology. *Journal of Neuroscience*, 24(45): 10099-10102.
75. Tizabi Y, Hauser SR, Tyler KY, Getachew B, Madani R, Sharma Y, Manaye KF. (2010). Effects of nicotine on depressive-like behavior and hippocampal volume of female WKY rats. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 34(1): 62-69.
76. Will CC, Aird F, Redei EE. (2003). Selectively bred Wistar-Kyoto rats: an animal model of depression and hyper-responsiveness to antidepressants. *Molecular Psychiatry*, 8(11): 925-932.
77. Zhang-James Y, Middleton FA, Faraone SV. (2013). Genetic architecture of Wistar-Kyoto rat and spontaneously hypertensive rat substrains from different sources. *Physiological Genomics*, 45(13): 528-538.
78. Lerman C, Caporaso N, Main D, Audrain J, Boyd NR, Bowman ED, Shields PG. (1998). Depression and self-medication with nicotine: the modifying influence of the dopamine D4 receptor gene. *Health Psychology*, 17(1): 56-62.
79. Audrain-McGovern J, Lerman C, Wileyto EP, Rodriguez D, Shields PG. (2004). Interacting effects of genetic predisposition and depression on adolescent smoking progression. *American Journal of Psychiatry*, 161(7): 1224-1230.
80. Bjorngaard JH, Gunnell D, Elvestad MB, Smith GD, Skorpén F, Krokan H, . . . Romundstad P. (2013). The causal role of smoking in anxiety and depression: a Mendelian randomization analysis of the HUNT study. *Psychological Medicine*, 43(4): 711-719.

81. Manley MJ, de Jonge P, Kershaw TS, Desai RA, Lin HQ, Kasl SV. (2009). Association of major depression with subtypes of nicotine dependence found among adult daily smokers: a latent class analysis. *Drug and Alcohol Dependence*, 104(1-2): 126-132.